Previous 10 |
Northland has initiated SPAC Oaktree Acquisition Corp. II (NYSE:OACB -0.3%) with an outperform rating ahead of its planned merger with Icelandic biotech Alvotech. The acquisition, announced in December, values Alvotech at $2.25B. Northland has a $15 price target (~51% upside based on Fri...
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023 All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including the ITC action brought forth in December 2021 Alvotech Holdings S.A. ...
Alvotech Holdings S.A. (“Alvotech”), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (“Oaktree II”) (NYSE: OACB), a publicly traded s...
Saint-Gobain acquires GCP for $32 per share, representing a premium of 21.12%. The tiny 0.72% spread on the GCP deal despite this being a cross-border deal, implies the market might be expecting a competing offer for. JACK wants to eat its TACO, paying a grande premium of over 66%...
Alvotech Holdings S.A., a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide to list on Nasdaq under the symbol “ALVO" through business combination with SPAC Oaktree Acquisition Corp. II (NYSE:OACB). The deal is ex...
Alvotech is a leading pure play biosimilar platform focused on the development and manufacture of high-quality biosimilar medicines for global markets. Biosimilars are therapeutic equivalents to biologics, a rapidly growing category of highly efficacious medicines Transa...
Alphyn Capital Management, LLC is a registered investment advisor focussed on a) great public companies that have the power to endure, with long runways to grow through reinvesting cash flows at high rates of return, run by talented and aligned operators and b) the occasional special situ...
Alphyn Capital Management, LLC is a registered investment advisor focussed on a) great public companies that have the power to endure, with long runways to grow through reinvesting cash flows at high rates of return, run by talented and aligned operators and b) the occasional special situ...
Alphyn Capital Management, LLC is a registered investment advisor focussed on a) great public companies that have the power to endure, with long runways to grow through reinvesting cash flows at high rates of return, run by talented and aligned operators and b) the occasional special situ...
News, Short Squeeze, Breakout and More Instantly...
Oaktree Acquisition Corp. II Class A Company Name:
OACB Stock Symbol:
NYSE Market:
Business Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol “ALVO” from June 16, 2022 on The Nasdaq Stock Market in New York and from June 23, 2022 on the Nasdaq First Nor...
Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval Oaktree Acquisition Corp. II (NYSE: OACB) (“OACB” or the “Company”) announced today that, assuming satisfaction of the conditions ...
The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara ® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of Alvotech’s biosimilars and biosimilar candidates, which includes AVT02 (ada...